Highlights

  • Racura Oncology (ASX: RAC) had its CPACS abstract accepted for a poster at the Global Cardio-Oncology Summit 2026, held 5-7 October 2026 in Williamsburg, Virginia, USA.
  • The abstract is a "Trial in Progress" report, sharing study design and early safety observations rather than final efficacy results.
  • The named authors span Racura in Sydney, the Cancer Care Foundation in Australia and Queen Mary Hospital in Hong Kong, reflecting a multicentre collaboration.
  • CEO Dr Daniel Tillett said the acceptance highlights growing interest in RC220's potential to address cardiotoxicity, a key limitation of anthracycline therapy.
  • Conference acceptance raises a company's scientific profile but is not clinical validation; CPACS remains an early Phase 1 study with no proven heart-protection or survival benefit.

Racura Oncology Limited (ASX:RAC) has secured a place on the programme of a focused scientific gathering. The company confirmed that its abstract describing the CPACS study has been accepted for a poster presentation at the Global Cardio-Oncology Summit 2026. For a clinical-stage biopharmaceutical company, having work accepted at a peer-attended summit is a meaningful step in building visibility among clinicians and researchers who work at the intersection of cancer treatment and heart health.

This article examines what that acceptance represents: what the Global Cardio-Oncology Summit is, what a "Trial in Progress" poster means, who the named authors and site collaborators are, and how conference exposure can lift a company's scientific profile. For Racura Oncology and ASX: RAC investors, the distinction matters: acceptance of an abstract endorses relevance and study design, not a verdict on whether the therapy works.

Inside the Announcement

According to Racura, the abstract titled "Cardioprotection & Anticancer Synergy (CPACS) - A Phase 1 Study of RC220 in Combination with Doxorubicin - Trial in Progress" was accepted for a poster presentation at the Global Cardio-Oncology Summit 2026, scheduled for 5-7 October 2026 in Williamsburg, Virginia, USA.

The Global Cardio-Oncology Summit is a specialist conference dedicated to cardio-oncology, the management of heart-related side effects arising from cancer therapies. Presenting there places Racura's work in front of clinicians and scientists specifically interested in problems such as chemotherapy-induced cardiac injury, a natural fit for CPACS and its ambition to combine anticancer activity with cardioprotection.

The title itself carries a signal. A "Trial in Progress" presentation is a recognised category at scientific meetings, used to describe a study under way rather than complete. Such presentations typically set out the trial's rationale, design, endpoints and enrolment status, and may share early safety observations. They are not intended to report final efficacy conclusions. Investors should therefore interpret the acceptance as the sharing of a study framework and its progress to date, attributed to the abstract and Racura, rather than a data readout claiming the treatment succeeds.

CEO and Managing Director Dr Daniel Tillett framed the acceptance in terms of interest rather than outcome. He noted growing interest in RC220's potential to address cardiotoxicity, one of the key limitations of anthracycline-based cancer therapy, and described CPACS as evaluating whether RC220 can be safely combined with doxorubicin to enhance anticancer activity and reduce cardiac injury. The wording is deliberately conditional: the study is testing a hypothesis, not confirming a result.

Background: Racura Oncology and RC220

Racura Oncology Limited is an ASX-listed biopharmaceutical company describing itself as a Phase 3 clinical-stage business with a mission to "silence cancer". Its lead asset is (E,E)-bisantrene, a small molecule that primarily acts by binding G-quadruplex DNA and RNA structures, leading to silencing of the MYC (c-MYC) oncogene, an important regulator of cancer growth. RC220 is Racura's proprietary formulation of (E,E)-bisantrene.

RC220 sits at the centre of three clinical programs: a Phase 3 program in acute myeloid leukaemia, the HARNESS-1 Phase 1 trial pairing RC220 with Tagrisso in mutant EGFR non-small cell lung cancer, and CPACS, the Phase 1 program combining RC220 with the anthracycline chemotherapy doxorubicin in solid tumours. CPACS is the program in focus here.

The clinical logic behind CPACS rests on a known problem. Anthracyclines such as doxorubicin remain central to many cancer regimens, but their use is limited by irreversible cardiotoxicity, meaning heart damage that cannot be undone. CPACS explores whether RC220 can be added to doxorubicin to both improve anticancer activity and reduce that cardiac harm. The supportive findings on this dual role come from preclinical work: RC220 combined with doxorubicin showed improved anticancer activity in human and murine tumour models and reduced cardiotoxicity in human cardiomyocytes and multiple animal cardiac models. Those are preclinical findings, not established clinical benefit in patients.

The Value and the Limits of a Conference Spotlight

Acceptance at a scientific summit is best understood as external attention rather than external proof. It tells the market that an independent programme committee considered the study relevant and well enough designed to share with a specialist audience, which can genuinely raise a small company's scientific profile.

Who is behind the abstract

The named authors give the abstract its scientific weight. They include Feroz Ahmad, Michelle Huh, Corli Merry, Daniel Tillett and Marinella Messina from Racura in Sydney, alongside Mahmood Alam of the Cancer Care Foundation in Australia and Roland Ching Yu Leung of Queen Mary Hospital in Hong Kong. This authorship spans the sponsor company and external clinical collaborators, and the inclusion of a Hong Kong site investigator reflects that CPACS is a genuinely multicentre effort.

The Hong Kong connection is notable. Enrolment in CPACS is ongoing in Australia and Hong Kong, with South Korea participation expected to commence. A named collaborator at Queen Mary Hospital signals that the trial has active clinical partners contributing to patient recruitment and study conduct across more than one jurisdiction.

What a "Trial in Progress" poster communicates

The abstract does share early observations, which should be attributed to the accepted abstract and the company. The first cohort of three patients was treated with RC220 at 40 mg/m2 and doxorubicin at 60 mg/m2, over up to five cycles. The independent Safety Review Committee reviewed this cohort and found an acceptable safety profile with no dose-limiting toxicity or other significant safety concerns, and allowed escalation to the next RC220 dose level of 80 mg/m2.

That is encouraging as an early safety signal, but limited by design. Three patients at the starting dose represent the very beginning of a dose-escalation study. An acceptable safety profile is not the same as demonstrated efficacy, and does not confirm that RC220 protects the heart or extends life. The abstract's own conclusion is measured: initial safety findings support continued dose escalation, and enrolment is ongoing.

Why profile still matters

For a company actively exploring partnerships, licence agreements and commercial opportunities to advance RC220, visibility among the right specialists can support relationships over time. A summit poster puts the CPACS design and rationale in front of the clinicians who understand cardio-oncology. This is where the value sits: awareness and credibility of the approach, not endorsement of a commercial outcome.

What It Could Mean for ASX: RAC

For Racura Oncology and ASX: RAC, the acceptance is a modest positive on the profile side of the ledger. It confirms that the CPACS approach is considered relevant by a specialist scientific community, and gives the company a platform to present its design and early safety observations to a targeted audience.

What it does not do is change the stage of development. CPACS remains a multicentre, open-label, two-part Phase 1 trial in adult patients with advanced solid tumours. Its primary objective is safety and tolerability, with secondary objectives covering maximum tolerated combined dose, pharmacokinetics, anti-tumour efficacy and exploratory cardioprotection biomarkers. Those are the questions the trial must answer over time, and a poster acceptance answers none of them. Investors should treat the news as a step in communication rather than clinical validation.

Limitations and Key Risks

CPACS is an early-stage Phase 1 trial, and a conference acceptance is not a clinical result. The distinction between safety and efficacy is central: an acceptable initial safety profile in three patients does not establish that RC220 works or protects the heart. Preclinical findings, however supportive, are not clinical proof.

Clinical risk is significant. Early dose-escalation studies can encounter dose-limiting toxicities, efficacy that does not eventuate, or cardioprotection signals not confirmed in larger cohorts. Regulatory risk remains substantial, as any path to approval requires far more extensive data across multiple trial phases. Funding risk is ever present for clinical-stage companies, which typically consume cash while advancing trials. Execution risk applies to a multicentre study enrolling across Australia, Hong Kong and, prospectively, South Korea. Commercialisation risk is real too: Racura is only exploring partnerships and licence arrangements, and nothing is signed. None of these risks is resolved by an abstract acceptance.

What Investors May Watch Next

Grounded in what the company has disclosed, several markers are worth following. The poster presentation at the Global Cardio-Oncology Summit on 5-7 October 2026 will be an occasion to see the CPACS design and progress communicated to peers. Beyond that, further Safety Review Committee outcomes as dose escalation proceeds to the 80 mg/m2 RC220 level will indicate how the tolerability picture develops.

Investors may also watch enrolment progress across the trial's sites, including the commencement of South Korean participation, and any move from dose escalation toward a dose-expansion cohort. Because CPACS includes exploratory cardioprotection biomarkers and later cardiac function measures, future disclosures on those endpoints would be relevant. Each should be assessed on its own merits rather than read into the summit acceptance.

Conclusion

The acceptance of Racura Oncology's CPACS abstract for a poster at the Global Cardio-Oncology Summit 2026 is a genuine, if modest, milestone for ASX: RAC. It reflects that a specialist scientific community sees the study's approach to combining anticancer activity with cardioprotection as worth presenting, and lifts the company's profile among the clinicians most attuned to cardiotoxicity. The named authorship, spanning Racura in Sydney, the Cancer Care Foundation and a Queen Mary Hospital collaborator in Hong Kong, underlines the multicentre nature of the work.

What the news is not is proof of benefit. A "Trial in Progress" poster shares design and early safety observations, and CPACS remains an early Phase 1 study whose central questions are unanswered. For Racura Oncology, the summit spotlight is a communication win to be welcomed for what it is, and understood for what it is not.